Compare Ascendis Pharma A/S (ASND) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Ascendis Pharma A/S trades at $256.37 (market cap $16.67B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.96. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| ASND | YINN | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $56.62 |
52-Week Low | $189.74 | $21.45 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
YINN, a leveraged ETF tracking Chinese equities, trades at $29.20, down 9.6% in 24 hours amid bearish technical signals. Key support lies at $29, with resistance at $30–31. The fund's structure amplifies volatility, and financial ratios are unavailable due to its ETF nature. Recent news highlights China's AI investments and trade resilience, but geopolitical tensions and regulatory scrutiny persist.
Outlook remains cautious due to leverage risks and China's economic uncertainties. Opportunities exist if Hang Seng rebounds, but investors face elevated volatility from US-China frictions and ETF decay. Risks outweigh near-term catalysts, warranting careful position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
